Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukemia in Adults Unable to Receive Intensive Chemotherapy

Oncology Practice Insider

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:

On October 16, 2020, the Food and Drug Administration granted regular approval to venetoclax (VENCLEXTA®, AbbVie Inc. and Genentech Inc.) in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy. Read more